Washington - Results from two multicenter, randomized, double-blind trials demonstrate that tacrolimus ointment 0.03 percent (Protopic) is a safe and effective treatment for mild to moderate atopic dermatitis in pediatric patients and adults.
SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Availability of Apremilast in US for Pediatric Patients Opens Avenues for Expanded Treatment Options and Oral Therapy
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
DPCP Immunotherapy Yields 61.8% Hair Regrowth Rate in Pediatric Alopecia Areata
“My Skin My Story” Provides Creative Outlet for Young Patients With Eczema